RT Journal Article
SR Electronic
T1 Comprehensive Treatment of Dactylitis in Psoriatic Arthritis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2295
OP 2300
DO 10.3899/jrheum.140879
VO 41
IS 11
A1 Rose, Shawn
A1 Toloza, Sergio
A1 Bautista-Molano, Wilson
A1 Helliwell, Philip S.
YR 2014
UL http://www.jrheum.org/content/41/11/2295.abstract
AB Dactylitis, a hallmark clinical feature of psoriatic arthritis (PsA) and other spondyloarthropathies, may also be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory drugs and local corticosteroid injections to treat dactylitis, although conventional disease-modifying antirheumatic drugs are also used. We performed a systematic literature review to determine the most efficacious current treatment options for dactylitis in PsA. Effect sizes were greatest for the biologic agents ustekinumab, certolizumab, and infliximab, suggesting that therapy with one of these agents should be initiated in patients with dactylitis. However, the limited data highlight the need for randomized, placebo-controlled trials, with dactylitis as a primary outcome, to determine a valid, reliable, and responsive clinical outcome measure for PsA patients with dactylitis.